{"name":"Institut Cancerologie de l'Ouest","slug":"institut-cancerologie-de-l-ouest","ticker":"","exchange":"","domain":"","description":"Institut Cancerologie de l'Ouest is a specialized oncology center dedicated to cancer research and treatment, with a focus on developing innovative therapies and improving patient outcomes.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"thrombogram","genericName":"thrombogram","slug":"thrombogram","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"thrombogram","genericName":"thrombogram","slug":"thrombogram","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPODc4SW1VWE1kRzZTX2tlTWZqSGNJajVZczU5TElvQ3QxczNFYWZUTkVINWxadVRPNTNaYVNZNm0yOUN4aUpSa2pnNHMxajFHbzZtTkpFbDlGenp2OXlaUUxfTGtzVFROYTBQanZHLS1JUE5Pb2xRUGxxRTFMcHVTQVVQTWNhSUx5UkhJVjZNZk1ScTVoekk5QjE1cnNMbWFTaEhTa2RWaEQtTWZtejZIVDc3cG1qdTRNdGl4NF9NLUl3QlpXdUVncHV3QWwtT2h3WHpWUU8yZG1RdlBjR1NlRDJPRTZaT3ZlYjlYaXgwQmw4UQ?oc=5","date":"2025-11-12","type":"trial","source":"PR Newswire","summary":"OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer - PR Newswire","headline":"OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}